All In Biotech

Drug Trial Radar · NCT00045955

Long-Term Safety Performance of Fexofenadine in Asthma

A Multicenter, Open-Label, Randomized, Parallel Groups Study to Assess the Long-Term Safety Performance of Fexofenadine Compared to Montelukast in Subjects With Asthma

Last checked: Nov 19, 2026Latest source record: Aug 21, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,200

Planned (sponsor's estimate)

Start

Feb 2002

Primary completion

Nov 2003

Study completion Nov 2003

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Sep 19, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the long-term safety performance of fexofenadine compared to montelukast in subjects with asthma

Conditions

  • Asthma

Interventions

  • Fexofenadine, Comparator = MontelukastDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety evaluation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aventis Pharmaceutical Inc.

    Bridgewater, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.